Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).
Chris Karlovich(Clovis Oncology (United States)), P. Mickey Williams(Leidos (United States)), Lyndsay N. Harris(National Institutes of Health), David R. Patton(National Cancer Institute), Jennifer S. LoCoco(Illumina (United States)), Traci Pawlowski(Illumina (United States)), Lisa M. McShane(National Cancer Institute), Amanda Peach(Frederick National Laboratory for Cancer Research), James H. Doroshow(National Cancer Institute), Alice P. Chen(National Institutes of Health), Phillip G. Febbo(Veracyte (United States)), Yao Fu(Illumina (United States)), Sorena Rahmanian(University of California San Diego), Biswajit Das(Frederick National Laboratory for Cancer Research), Naoko Takebe(National Institutes of Health), Li Chen(Harvard University), Jessica Li(Universidad San Carlos), Robin Harrington(Frederick National Laboratory for Cancer Research), Jennifer L. Silhavy(Howard Hughes Medical Institute), Ting-Chia Chang(Frederick National Laboratory for Cancer Research)
Cited by 1
Related Papers
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0
|Nature Protocols|2011|1.9k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k